Oligometastatic prostate is a hot topic and an area of growing interest in daily urological oncology practice, mandating a multidisciplinary team approach. It is however variably defined and high-quality evidence guiding optimal management is limited. The initial question is how best to define this state, as prognosis will be dependent on the imaging modality used (conventional v functional), the tissues involved (nodal v bone v visceral), the tempo of disease and the number of lesions detected (1 v 3 v 5 v more). Timing is also critical, given that the oligometastatic state can be detected either at diagnosis (synchronous) or following local treatment (metachronous). There are options regarding the integration of local treatments with systemic therapy and consideration must be given to defining relevant endpoints. There are also technical challenges associated with delivering ablative or potentially immuno-stimulatory radiotherapy to such lesions. Here we will explore the biology, technology and ongoing clinical trial activity around the use of stereotactic ablative body radiation (SABR) techniques in the oligometastatic state of prostate cancer.